Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 2, 2012, Pages 226-232

  Biancini, Giovana B ^a,b   Vanzin, Camila S ^a,b   Rodrigues, Daiane B ^b   Deon, Marion ^b   Ribas, Graziela S ^a,b   Barschak, Alethéa G ^c   Manfredini, Vanusa ^d   Netto, Cristina B O ^b   Jardim, Laura B ^a,b   Giugliani, Roberto ^a,b   Vargas, Carmen R ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^d UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

Antioxidant defense; Fabry disease; Globotriaosylceramide; Inflammation; Oxidative stress; Reactive species

Indexed keywords

CATALASE; GLOBOTRIAOSYLCERAMIDE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; ERYTHROCYTE; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN URINE LEVEL; URINALYSIS;

ADULT; ALPHA-GALACTOSIDASE; ANTIOXIDANTS; CATALASE; ENZYME REPLACEMENT THERAPY; ERYTHROCYTES; FABRY DISEASE; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TRIHEXOSYLCERAMIDES; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; YOUNG ADULT;

EID: 83255165401     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.11.001     Document Type: Article

References (43)

1. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. McGraw-Hill Inc., New York. eighth ed. C.R. Scriver, W.A. Sly, A.L. Beaudet, D. Valle (Eds.).
2. El Dib R.P., Pastores G.M. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst. Rev. 2010, 5:CD006663.
3. Moore D.F., Ye F., Brennan M.L., Gupta S., Barshop B.A., Steiner R.D., Rhead W.J., Brady R.O., Hazen S.L., Schiffmann R. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J. Magn. Reson. Imaging 2004, 20:674-683.
4. Bodary P.F., Shen Y., Vargas F.B., Bi X., Ostenso K.A., Gu S., Shayman J.A., Eitzman D.T. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005, 111:629-632.
5. Moore D.F., Scott L.T.C., Gladwin M.T., Altarescu G., Kaneski C., Suzuki K., Pease-Fye M., Ferri R., Brady R.O., Herscovitch P., Schiffmann R. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001, 104:1506-1512.
6. Halliwell B. Free radicals, antioxidants, and human disease: curiosity cause or consequence?. Lancet 1994, 344:721-724.
7. Polidori M.C., Frei B., Cherubini A., Nelles G., Rordorf G., Keaney J.F., Schwamm L., Mecocci P., Koroshetz W.J., Beal M.F. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic. Biol. Med. 1998, 25:561-567.
8. Terman A., Kurz T., Gustafsson B., Brunk U.T. Lysosomal labilization. IUBMB Life 2006, 58:531-539.
9. Terman A., Brunk U.T. Oxidative stress, accumulation of biological 'garbage', and aging. Antioxid. Redox Signal. 2006, 8:197-204.
10. Brunk U.T., Neuzil J., Eaton J.W. Lysosomal involvement in apoptosis. Redox Rep. 2001, 6:91-97.
11. Shen J.-, Meng X.-, Moore D.F., Quirk J.M., Shayman J.A., Schiffmann R., Kaneski C.R. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 2008, 95:163-168.
12. Esterbauer H., Cheeseman K.H. Determination of aldehydic lipid peroxidation products: malondialdehyde and 4-hydroxynonenal. Methods Enzymol. 1990, 186:407-421.
13. Kirschbaum B. Correlative studies of urine fluorescence and free radical indicators. Clin. Nephrol. 2002, 58:344-349.
14. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990, 186:464-478.
15. Aksenov M.Y., Markesbery W.R. Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer's disease. Neurosci. Lett. 2001, 302:141-145.
16. Browne R.W., Armstrong D. Reduced glutathione and glutathione disulfide. Methods Mol. Biol. 1998, 108:347-352.
17. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
18. Auray-Blais C., Cyr D., Ntwari A., West M., Cox-Brinkman J., Bichet D.G., Germain D.P., Laframboise R., Melançon S.B., Stockley T., Clarke J.T.R., Drouin R. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab. 2008, 93:331-340.
19. Lowry O.H., Rosenbrough N.J., Farr A.I., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
20. Futerman A.H., Van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 2004, 5:554-565.
21. Walkley S.U. Pathogenic cascades in lysosomal disease - why so complex?. J. Inherit. Metab. Dis. 2009, 32:181-189.
22. Vitner E.B., Platt F.M., Futerman A.H. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 2010, 20423-20427.
23. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2006, Oxford University Press, New York. fourth ed.
24. Toyokuni S. Persistent oxidative stress in cancer. FEBS Lett. 1995, 358:1-3.
25. Mantovani G., Macciò A., Madeddu C., Mura L., Gramignano G., Lusso M.R., Mulas C., Mudu M.C., Murgia V., Camboni P., Massa E., Ferreli L., Contu P., Rinaldi A., Sanjust E., Atzei D., Elsener B. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int. J. Cancer 2002, 98:84-91.
26. Blackburn R.V., Spitz D.R., Liu X., Galoforo S.S., Sim J.E., Ridnour L.A., Chen J.C., Davis B.H., Corry P.M., Lee Y.J. Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells. Free Radic. Biol. Med. 1999, 26:419-430.
27. López-Lázaro M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol. Med. 2010, 16:144-153.
28. Barschak A.G., Sitta A., Deon M., Barden A.T., Dutra-Filho C.S., Wajner M., Vargas C.R. Oxidative stress in plasma from maple syrup urine disease patients during treatment. Metab. Brain Dis. 2008, 23:71-80.
29. Vargas C.R., Wajner M., Sirtori L.R., Goulart L., Chiochetta M., Coelho D. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim. Biophys. Acta 2004, 1688:26-32.
30. Sitta A., Barschak A.G., Deon M., Barden A.T., Biancini G.B., Vargas P.R., de Souza C.F., Netto C., Wajner M., Vargas C.R. Effect of short- and long-term exposition to high phenylalanine blood levels on oxidative damage in phenylketonuric patients. Int. J. Dev. Neurosci. 2009, 27:243-247.
31. Ribas G.S., Manfredini V., de Mari J.F., Wayhs C.Y., Vanzin C.S., Biancini G.B., Sitta A., Deon M., Wajner M., Vargas C.R. Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of l-carnitine supplementation. Int. J. Dev. Neurosci. 2010, 28:127-132.
32. Filippon L., Vanzin C.S., Biancini G.B., Pereira I.N., Manfredini V., Sitta A., Peralba M.C.R., Schwartz I.V.D., Giugliani R., Vargas C.R. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy. Mol. Genet. Metab. 2011, 103:121-127.
33. Filippon L., Wayhs C.A.Y., Atik D.M., Manfredini V., Herber S., Carvalho C.G., Schwartz I.V.D., Giugliani R., Vargas C.R. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy. Mutat. Res. 2011, 721:206-210.
34. Halliwell B. Reactive species and antioxidants. redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006, 141:312-322.
35. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
36. Moore D.F., Goldin E., Gelderman M.P., Robinson C., Baer J., Ries M., Elkahloun A., Brady R.O., Schiffmann R. Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease. Acta Paediatr. 2008, 97:48-52.
37. Rahman P., Gladman D.D., Wither J., Silver M.D. Coexistence of Fabry's disease and systemic lupus erythematosus. Clin. Exp. Rheumatol. 1998, 16:475-478.
38. Whybra C., Schwarting A., Kriegsmann J., Gal A., Mengel E., Kampmann C., Baehner F., Schaefer E., Beck M. IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr. Nephrol. 2006, 21:1251-1256.
39. Martinez P., Aggio M., Rozenfeld P. High incidence of autoantibodies in Fabry disease patients. J. Inherit. Metab. Dis. 2007, 30:365-369.
40. Davies M.J., Fu S., Wang H., Dean R.T. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic. Biol. Med. 1999, 27:1151-1163.
41. Dalle-Donne I., Aldini G., Carini M., Colombo R., Rossi R., Milzani A. Protein carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 2006, 10:389-406.
42. Rozenfeld P., Agriello E., De Francesco N., Martinez P., Fossati C. Leukocyte perturbation associated with Fabry disease. J. Inherit. Metab. Dis. 2009, 155:1-11. 10.1007/s10545-009-1060-9.
43. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutière B., Altarescu G., McCarron R., Schiffmann R. Profile of endothelial and leukocyte activation in Fabry patients. Ann. Neurol. 2000, 47:229-233.